University of Rochester clinical trial pipeline

14 trials changed in the last 30 days: 1 stopped, 8 with notable changes, 5 with minor changes only.

1. Stopped

   RSIVI · Sucrosomial Vs Intravenous Iron for Preoperative Anemia

   Withdrawn before enrolling

   Sponsor's reason: Study withdrawn due to lack of funding and the company's decision not to pursue the IND. No participants were enrolled.

   University of Rochester·Phase 4· NCT07287371· Registry history of NCT07287371 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

2. Notable

   PET Adapted Therapy and Non-invasive Monitoring for Previously…PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

   Primary completion pushed from Jun 1, 2026 to Dec 1, 2026

   University of Rochester·Phase 2· NCT03758989· Registry history of NCT03758989 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

3. Notable

   Visual Attention and Eye Movements

   Primary completion pushed from Sep 1, 2026 to Sep 2027

   Also in this update: Study completion pushed from Sep 1, 2026 to Sep 1, 2027

   University of Rochester·Not specified· NCT03298737· Registry history of NCT03298737 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

4. Notable

   ERADICATE-AF · Renal Denervation + PVI vs PVI Alone for…ERADICATE-AF · Renal Denervation + PVI vs PVI Alone for Persistent AF

   Primary and study completion pushed from Jun 30, 2026 to Jul 31, 2027

   University of Rochester·Not applicable· NCT05116384· Registry history of NCT05116384 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

5. Notable

   Visual and Vestibular Motion Perception Study

   Primary completion pushed from Sep 1, 2026 to Sep 1, 2030

   Also in this update: Study completion pushed from Sep 1, 2027 to Sep 1, 2032

   University of Rochester·Not applicable· NCT04142697· Registry history of NCT04142697 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

6. Notable

   SBAT for Health Equity

   Primary completion pushed from Jul 31, 2030 to Jul 31, 2032

   Also in this update: Study completion pushed from Dec 31, 2030 to Dec 31, 2032

   University of Rochester·Not applicable· NCT05744869· Registry history of NCT05744869 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

7. Notable

   Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP · DLBCL

   Primary and study completion pushed from Jul 31, 2026 to Jul 31, 2027

   University of Rochester·Phase 2· NCT04594798· Registry history of NCT04594798 on ClinicalTrials.gov (opens the registry)

   Updated Sep 18, 2026

8. Notable

   Steroid Sparing Treatment With in Newly Diagnosed Transplant…Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible · Multiple Myeloma

   Primary and study completion pushed from Jul 31, 2026 to Sep 8, 2027

   University of Rochester·Phase 2· NCT04635189· Registry history of NCT04635189 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

9. Notable

   Music Therapy to Improve Dental Procedure Tolerance and Reduce…Music Therapy to Improve Dental Procedure Tolerance and Reduce Distress · Intellectual and Developmental Differences

   Primary endpoint(s) modified

   And 3 more changes in the last 30 days

   University of Rochester·Not applicable· NCT07806201· Registry history of NCT07806201 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.